The current financial score of ADMA Biologics Inc is 8.88. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 124.39M, representing a year-over-year increase of 1.98%, while its net profit experienced a year-over-year increase of 10.53%.
The current valuation score of ADMA Biologics Inc is 6.95. Its current P/E ratio is 15.90, which is 743.41% below the recent high of 134.13 and 4073.91% above the recent low of -632.00.
The current earnings forecast score of ADMA Biologics Inc is 7.50. The average price target is 17.00, with a high of 21.00 and a low of 12.00.
The current price momentum score of ADMA Biologics Inc is 4.15. Currently, the stock price is trading between the resistance level at 11.98 and the support level at 10.06, making it suitable for range-bound swing trading.
The current institutional shareholding score of ADMA Biologics Inc is 10.00. The latest institutional shareholding proportion is 94.06%, representing a quarter-over-quarter decrease of 3.88%.
The current risk assessment score of ADMA Biologics Inc is 5.94. The company's beta value is 0.74. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.